An orally active, potent p38 MAPK inhibitor that potently inhibits ex vivo LPS‐induced TNFα secretion with an IC50 of 44 ng/mL (115 nM); inhibits LPS‐stimulated TNFα release in the human whole blood assay with IC50 of 24 nM; shows antiinflammatory activity for treatment of acute as opposed to chronic inflammation disorders.COPD Phase 1 Clinical.